Rationale: Primary cutaneous aspergillosis in immunocompromised patients has been well described in extensive investigations. However, in immunocompetent hosts, primary cutaneous infection of aspergillus occurs rarely, and remains poorly characterized.
Introduction
In recent years, there has been a remarkable increase in the occurrence of primary cutaneous aspergillosis in immunocompromised patients. Primary cutaneous aspergillosis in immunocompromised patients has been well described in extensive investigations. However, in immunocompetent hosts primary cutaneous infection of aspergillus occurs rarely and therefore remains poorly characterized. In this report, we present a case of primary cutaneous aspergillosis manifested by erythematous plague covered with flava eschar.
Methods
An approval from the ethics committee of the Qilu Hospital of Shandong University was obtained for this case report study. The detailed information regarding this study has been fully disclosed to the patient and his parents, and informed consent has been obtained from his parents.
Case report
A 9-year-old patient presented with erythematous plague on his left cheek, he was scratched by a branch 3 months ago and a papule appeared on the wound site several days later, which progressively evolved into a slight tender but otherwise unremarkable nodule. Erythromycin ointment had been administered for a month. The lesion did not respond to erythromycin ointment, developed into an erythematous, irregular-shaped plague measuring 3 Â 4 cm covered by flava eschar (Fig. 1) . The patient has been living in an orchard since he was born and prior to onset of the lesion he was healthy. History of using immunosuppressive agent or immunodeficient disorders was denied. The physical examination revealed nothing but the cutaneous lesion on the right side of the face. Blood routine, T and B lymphocyte subpopulation, and renal and hepatic function Editor: N/A. XL and JY contributed equally to this manuscript.
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tests were within normal limits. Skin biopsy was performed. Histopathologically, hematoxylin eosin staining of the skin biopsy specimen demonstrated dermal diffuse and nodular granulomatous infiltration with large amounts of lymphocytes, multinucleated giant cell, eosinophil, and neutrophil. Cultures of the biopsy material from the lesion on Sabouraud dextrose agar at 25°C and 37°C grew numerous and identical fungal colonies, which were dense, smoky, gray-green with a slight creamy-white reverse (Fig. 2) . Microscopically, it was characterized by septate and hyaline hyphae, columnar conidia 2.5 to 3 mm in diameter which were produced in chains basipetally from single palisadelike layer phialides that were borne directly on broadly clavate vesicles (Fig. 3) . On the basis of the above-mentioned characteristics the pathogen was identified as Aspergillus Fumigatus. Combining the clinical manifestation and histopathological and culture results, aspergillosis was diagnosed. Treatment included oral itraconazole at a dose of 75 mg/d and local wound care with ciclopirox olamine ointment. After half a month, a partial resolution and a decrease in tenderness indicated gradual improvement, and a complete recover was achieved 2 months later. No adverse events were reported during the treatment.
Discussion
We present a case of primary cutaneous aspergillosis in an immunocompetent patient. Aspergillus species are ubiquitous molds that can be isolated from the soil, air, dust, plants, skin, and nails. [1] The previous study has shown that factors increasing the risk of aspergillosis include severe debilitating illnesses (e.g., cancer, burns, and chronic granulomatous diseases) and neutropenia (e.g., patients with leukemia, cytotoxic chemotherapy, corticosteroid therapy, broad-spectrum antibiotic therapy, and human immunodeficiency virus infection). [2, 3] However, no immunodeficient diseases or history of use of immunosuppressive agents was found in our patient.
The host defence mechanism against aspergillus species involves immunologic barriers and physical cutaneous barriers. Macrophages phagocytize aspergillus conidial, whereas polymorphonuclear leukocytes and monocytes damage aspergillus hyphae via oxidative and nonoxidative mechanism. [4] Of great importance as well is the keratin and epidermal barriers of the skin that serve as an additional front line of mechanical host defence. [1] It is important to note that our patient developed cutaneous Aspergillus infection despite his apparent immunocompetent state. We propose that the long-term inhabitation in the orchard that places the patient in exposure to high spore counts, together with the cutaneous injury-a portal of entry for the causative organism contributes to the infection.
The initial lesions of cutaneous aspergillosis may appear in different forms, including macules, papules, nodules, or plaques. [5] The various clinical manifestations of cutaneous aspergillosis constitute a great diagnostic and therapeutic challenge, which in turn makes the repeated biopsy of a skin lesion for microbiology and pathology a prerequisite for a definitive diagnosis.
Once the diagnosis of aspergillosis is established, the subsequent efforts should be directed at determining whether the infection has disseminated to or arisen from extracutaneous site and the underlying impairment of patient immune system. Besides, the immune status of the infected patient should be evaluated as the host underlying immunity plays a critical role in the treatment of aspergillosis. [6] Schimmelpfennig et al [7] reported a case in which aspergillosis developed and progressed in a patient with chronic myeloid leukemia despite prompt therapy with amphotericin B. Resistance testing of Aspergillus fumigatus isolated from the lesion against amphotericin B showed that this species is fully sensitive to amphotericin B in vitro. The ineffectiveness of antifungal treatment in vivo associated with immunodeficient state necessitates approaches to the augmentation or the restoration of host defences. In our case, the patient responded very well to oral itraconazole treatment, which is at least in part, thanks to his immunocompetent state.
As cutaneous aspergillosis could manifest in different ways, close attention should be paid to lesions that do not respond to antibacterial treatments, and clinicians should remain alert to the possibility of aspergillus infection even in an immunocompetent patient. Subsequent biopsy for microbiology and pathology is warranted for a well-established diagnosis.
